API | elvucitabine

elvucitabine Report issue

Small molecule Experimental

AACT ChEMBL MeSH PubChem

Active Ingredient History

NOW

Elvucitabine is an experimental nucleoside reverse transcriptase inhibitor (NRTI), developed by Achillion Pharmaceuticals, Inc. for the treatment of HIV infection. ^Wikipedia

Chemistry

SMILES: Nc1nc(=O)n([C@@H]2C=C[C@H](CO)O2)cc1F
InChIKey: HSBKFSPNDWWPSL-VDTYLAMSSA-N
Mol. Mass: 227.19
ALogP: -0.59 Partition coefficient
ChEMBL Molecule:
elvucitabine

More Chemistry

Pharmacology

Mechanisms of Action:
- Protein P (Hepatitis B virus) ^UniProt
- Reverse transcriptase/RNaseH (Human immunodeficiency virus 1) ^UniProt
- Reverse transcriptase (Human immunodeficiency virus 2) ^UniProt
Multi-specific: Missing data
Black Box: No
Availability: Missing data
Delivery Methods: Missing data
Pro Drug: No

ach-126443 | ach-126-443 | ach126-443 | beta-l-fd4c | elvucitabine

Organizations (12)

Research & Development (12)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Marketing (0)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Indications (3)

Approved Indications (0)

Experimental Indications - Clinical Trial Phases 1-4 (3)

Hepatitis B, Chronic (Phase 2)

HIV (Phase 2)

HIV Infections (Phase 2)

Overview

Highest Phase: Phase 2
# of Trials: 8
# of Trial Organizations: 12

Trials by Phase

Trial	Phase	Start Date	Organizations	Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue